BLUEMTEC Co (439580) Fair Value & Analysis
Healthcare · KR · Market cap 55.6B KRW
Fair value as of: Jul 22, 2026
From 10 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 523.50 KRW to 523.18 KRW (−0.1%) since Jun 25, 2026. Share price +3.6% over the past month.
Below-average quality, and screening another 71% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (873.52 KRW). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (172.84 KRW to 873.52 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
32‑month range 1,466 KRW – 17,000 KRW · fair‑value band 172.84 KRW – 873.52 KRW · the 1,790 KRW price screens above the 523.18 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
BLUEMTEC Co (439580) currently trades at 1,790 KRW, while our model-based Fair Value estimate is 523.18 KRW, implying the stock looks roughly 70.8% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, BLUEMTEC Co generated revenue of 196B KRW at a net margin of -0.1%. Revenue grew 28.9% year over year. It earns a return on equity of -0.6%. Net debt stands at 21.8B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 172.84 KRW (bear case) to 873.52 KRW (bull case); at 1,790 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 74% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -71%, 439580 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Growth DCF (2,388 KRW) versus Multiples (498.03 KRW). Highest evidence: Growth DCF (80).
Notify me when 439580 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BLUEMTEC Co., Ltd. operates a pharmaceutical distribution platform in South Korea and internationally. It is also involved in the healthcare digital marketing, IT development, fulfilment, pharmaceutical distribution data, and medical staff matching, and logistics businesses. The company was founded in 2015 and is headquartered in Yongin-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BLUEMTEC Co reported revenue of 186B KRW in FY2025 versus 51.9B KRW in FY2021, a compound +37.6%/yr. Reported net income was −4.5B KRW in FY2025.
439580 screens 71% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare BLUEMTEC Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BLUEMTEC Co (439580) overvalued or undervalued?
What is the fair value of 439580?
What is the quality score of 439580?
What is the revenue of BLUEMTEC Co (439580)?
What is the net profit margin of 439580?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BLUEMTEC Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.